Skip to main content
. 2020 Oct 14;71(2):502–513. doi: 10.1007/s12020-020-02475-2

Fig. 3.

Fig. 3

Time to death or subsequent PD in patients with PD, while receiving placebo in the core study who switched to lanreotide autogel/depot in the OLE. Data are from a subset of the intention-to-treat population with months approximated based on 4 weeks per month. OLE open-label extension, PD progressive disease